logo

For the Inventor, By the Inventor

Foster City, CA, United States of America

Hui Tian

This inventor holds 18 USPTO granted patents and 9 published patent applications and 3 EPO patents, primarily in Metabolic Disorders. Top assignees: Ngm Biopharmaceuticals, Inc., Amgen Inc., Other. Active years: 2004-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hui Tian. Retrieved from https://idiyas.com/inventor/hui-tian-h0ywc0rg

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 18 

% Patents Active = 38.9

 

Average Co-Inventor Count = 3.0

ph-index = 5

Forward Citations = 55(Granted Patents)


Company Filing History:

goldMedal10 out of 73 
 
Ngm Biopharmaceuticals, Inc.
 patents
silverMedal7 out of 2,076 
 
Amgen Inc.
 patents
bronzeMedal1 out of 834,601 
Other
 patents

Years Active: 2004-2023

Loading Chart...
Loading Chart...
Areas of Expertise:
LEAP2 Antibody
FGF19 Polypeptides
Bile Acid Homeostasis
Metabolic Disorders
Cancer Treatment
Receptor Ligands
Sitosterolemia
ABCG8 Vectors
Pruritus Treatment
Growth Hormone
Screening Methods
18 patents (USPTO):Explore Patents
1. 11548942 - Methods of treating a wasting syndrome, increasing growth hormone levels, and increasing GHSR activity with a LEAP2 antibody (2023-01-10),
2. 11370841 - Methods of treating fibroblast growth factor 19-mediated cancers and tumors (2022-06-28),
3. 11358995 - Compositions and methods of use for treating metabolic disorders (2022-06-14),
4. 11241481 - Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases (2022-02-08),
5. 11141460 - Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders (2021-10-12),
6. 10781253 - LEAP2 binding agents and compositions thereof (2020-09-22),
7. 10744185 - Methods of using variants of FGF19 polypeptides for the treatment of pruritus (2020-08-18),
8. 10456449 - Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases (2019-10-29),
9. 10434144 - Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders (2019-10-08),
10. 9834586 - Compositions and methods of use for treating metabolic disorders (2017-12-05),
11. 8257934 - Screening methods using sitosterolemia susceptibility gene (SSG) polypeptides (2012-09-04),
12. 8022061 - N-aryl pyrazole compounds, compositions, and methods for their use (2011-09-20),
13. 7662376 - Sitosterolemia susceptibility gene (SSG): compositions and methods of use (2010-02-16),
14. 7229816 - Sitosterolemia susceptibility gene (SSG) polypeptides (2007-06-12),
15. 7189524 - Receptor ligands and methods of modulating receptors (2007-03-13),

Title: Hui Tian: A Leader in Innovative Treatments for Metabolic and Neuroendocrine Disorders

Introduction

Hui Tian, based in Foster City, CA, is a prominent inventor known for his groundbreaking work in the fields of metabolic and neuroendocrine disorders. With an impressive portfolio of 18 patents, Tian has significantly contributed to the development of advanced therapeutic methods, particularly in treating conditions like obesity, diabetes, and various cancers.

Latest Patents

Among his latest patents, Hui Tian has developed methods of treating a wasting syndrome, increasing growth hormone levels, and enhancing GHSR activity with a LEAP2 antibody. These innovative binding agents are designed to modulate the interaction between liver-expressed antimicrobial peptide 2 (LEAP2) and the growth hormone secretagogue receptor (GHSR). His research provides new avenues for addressing neuroendocrine and metabolic diseases such as cachexia, anorexia, obesity, diabetes, acromegaly, gigantism, and Prader-Willi syndrome.

Additionally, Tian has patented methods for treating fibroblast growth factor 19-mediated cancers and tumors. These methods involve administering anti-IL-6 antibodies or inhibitors of the STAT3/JAK signaling pathway, demonstrating his commitment to finding effective treatments for serious health challenges.

Career Highlights

Throughout his career, Hui Tian has worked with leading biotechnology firms, including NGM Biopharmaceuticals, Inc. and Amgen Inc. His contributions in these organizations have facilitated significant advancements in drug development focused on treating complex diseases.

Collaborations

Hui Tian has collaborated with esteemed colleagues, including Lei Ling and Bei Shan. Together, they have contributed to the advancement of therapeutic technologies that are expected to have lasting impacts on patient care.

Conclusion

Hui Tian's innovative approaches and substantial patent portfolio underline his expertise in addressing challenging health conditions. His work continues to inspire advancements in therapeutic strategies, paving the way for new treatment methodologies that can significantly enhance patients' lives. With ongoing research and development efforts, Tian remains a pivotal figure in the realm of biotechnology and therapeutic innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…